| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for Sanbio BV > News item |
Tm Bioscience signs deal with Sanbio to commercialize ID-Tag in the Netherlands
By E. Janene Geiss
Philadelphia, June 16 - Tm Bioscience Corp. said Friday that it has signed a distribution agreement with Sanbio BV to commercialize the ID-Tag Respiratory Viral Panel from Tm in the Netherlands.
The ID-Tag panel detects and discriminates between 20 respiratory viruses including avian Flu and SARS, according to a company news release.
Under the agreement, Sanbio said it will have the exclusive right to market and sell the ID-Tag panel in the Netherlands.
Tm said it will supply Sanbio with finished packaged product and will receive revenue from the sale of such finished packaged product.
The company said it intends to complete a series of distribution agreements across Europe in the coming months as it prepares for commercialization of the test upon gaining European regulatory clearance, which is expected this year.
The ID-Tag Respiratory Viral Panel is a unique molecular diagnostic test that has the potential to play a key role in the diagnosis of respiratory viruses in clinical settings in addition to its role as a tool to assist in managing the pandemic threat of avian flu.
Tm said its strategy is to make the ID-Tag panel product a worldwide standard for use in patient and resource management in clinical environments, as well as for use in public health programs.
Sanbio is a leading distribution company based in The Netherlands that supplies products for research and diagnostics in Belgium, The Netherlands and Luxemburg to universities, research institutes, pharmaceutical and biotech companies.
Tm Bioscience is a Toronto DNA-based diagnostics company that develops genetic tests.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.